Mesoblast Limited (ASX: MSB)
Australia
· Delayed Price · Currency is AUD
2.870
+0.090 (3.24%)
Jan 21, 2025, 4:10 PM AEST
Mesoblast Revenue
In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M USD, down -21.32%. Mesoblast had revenue of $1.26M in the quarter ending June 30, 2024, a decrease of -41.23%.
Revenue
$5.90M
Revenue Growth
-21.32%
P/S Ratio
n/a
Revenue / Employee
$80.85K
Employees
73
Market Cap
3.51B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 22.18B |
Pro Medicus | 161.50M |
Cochlear | 2.24B |
Sonic Healthcare | 8.97B |
Telix Pharmaceuticals | 645.68M |
Ramsay Health Care | 16.66B |
Ansell | 2.43B |
Sigma Healthcare | 3.48B |
Mesoblast News
- 10 days ago - Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 21 days ago - Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
- 4 weeks ago - This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Benzinga
- 4 weeks ago - What's Going On With Mesoblast Shares Thursday? - Benzinga
- 4 weeks ago - Mesoblast Finally Gets Its Approval In GVHD: Where Now? - Seeking Alpha
- 4 weeks ago - Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga
- 4 weeks ago - Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga
- 4 weeks ago - Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga